Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804204 | 1.00 | MEN1 (0.41) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4807594 | 1.00 | MEN1 (0.41) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4807929 | 0.84 | SLC1A3 (0.45) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4807936 | 0.84 | SLC1A3 (0.45) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9610150 | 0.83 | SLC1A3 (0.41) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17170474 | 0.80 | CYP2C9 (0.39) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17170399 | 0.80 | CYP2C9 (0.39) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL17170481 | 0.80 | CYP2C9 (0.39) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28563227 | 0.79 | SLC1A3 (0.46) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28557184 | 0.79 | SLC1A3 (0.46) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446125-B2 | Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2008-11-04 | — | — | US | disclosed |
| US-20060211630-A1 | Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211630-A1 | Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders | ITGB5, ITGA5, ITGAV | MEN1 1765/4885KMT2A 3779/4885SLC1A3 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.